Loading Events

Register for Event

7:45 – 8:50 am


8:50 – 9:00 am


9:00 – 9:45 am

Identifying Microbiome-Encoded Drug Metabolizing Enzymes
Andrew Goodman (Yale University)

9:45 – 10:30 am

Integrating Drug Metabolism via the Gut Microbiome into the Drug Discovery and Development Paradigm
Jason Boer (Incyte Pharmaceuticals)

10:30 – 10:45 am

Coffee Break

10:45 – 11:30 am

Functional Characterization of Drug Metabolizing Enzymes at the Host-Gut Microbiome Interface
Aaron Wright (Pacific Northwest National Laboratory and Washington State University)

11:30 – 12:15 pm

A Prevalent Operon from the Human Gut Microbiome is Responsible for the Inactivation of Fluoropyrimidine Anticancer Drugs
Peter Spanogiannopoulos (University of California San Francisco)

12:15 – 1:15 pm


1:15 – 1:35 pm

A Multi-omic Approach to Understand the Development of the Gut-Liver Axis
Young investigator (Joseph Dempsey, University of Washington)

1:35 – 2:20 pm

Gut-Liver Axis and Environmental Chemical Exposures
Julia Cui (University of Washington)

2:20 – 2:35 pm

Coffee Break

2:35 – 3:20 pm

Microbiome Determinants of Arsenic Toxicity
Seth Walk (Montana State University)

3:20 – 4:05 pm

FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid
David Shen (University of Pennsylvania)

Share This Post, Choose Your Platform!